SCHEDULE: Lagoda Investment Management Adjusts VolitionRx Stake

Lagoda Investment Management, L.P. and related entities have filed an amendment to their Schedule 13D, reporting a beneficial ownership of 5.9% in VolitionRx Limited, with a minor sale of shares noted.

Summary

• This filing is an amendment (Amendment No. 1) to a previously filed Schedule 13D concerning VolitionRx Limited.
• The reporting persons, including Lagoda Investment Management, L.P., Lagoda Investment Management, LLC, and Fatima Dickey, collectively beneficially own 1,650,505 shares of VolitionRx Limited's common stock.
• This ownership represents approximately 5.9% of the outstanding common stock.
• The total beneficial ownership includes 1,479,450 shares of common stock and warrants exercisable for an additional 171,055 shares.
• The calculation of the percentage ownership is based on 27,903,326 shares outstanding as of September 14, 2026, plus the shares issuable upon warrant exercise.
• On September 16, 2026, the Investment Manager sold 1,500 shares of common stock in an open-market transaction at $0.2855 per share.
• No other transactions in the common stock have been effected by the reporting persons since September 4, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, primarily due to a minor stock sale and the nature of a Schedule 13D amendment which typically indicates ongoing or adjusted investment strategies rather than significant positive developments.

Positives

• The reporting persons maintain a significant beneficial ownership stake of 5.9% in VolitionRx Limited, indicating continued investment interest.
• The filing clearly outlines the components of beneficial ownership, including direct shares and exercisable warrants.

Negatives

• A minor sale of 1,500 shares occurred on September 16, 2026, at $0.2855 per share, indicating a slight reduction in holdings.
• The filing is an amendment to a Schedule 13D, which often signifies adjustments to an investment strategy rather than a new, positive development.

Risks

• The filing does not explicitly detail new risks, but the nature of Schedule 13D filings implies ongoing monitoring of potential risks associated with the investment.
• The specific price of $0.2855 per share for the sold shares could be indicative of market sentiment or the reporting person's valuation at that time.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from VolitionRx Limited. It primarily reports on the current beneficial ownership and recent transaction activity of the reporting persons.

Management Comments

• "This Amendment No. 1 to Schedule 13D (this "Amendment") amends and supplements the Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission on September 4, 2026 (the "Schedule 13D")."
• "Capitalized terms used but not defined in this Amendment have the meanings given to them in the Schedule 13D."
• "Except as specifically amended by this Amendment, the Schedule 13D remains unchanged."
• "As of the date of this Amendment, each of the Reporting Persons may be deemed to beneficially own, in the aggregate, 1,650,505 shares of Common Stock..."
• "On September 16, 2026, the Investment Manager sold 1,500 shares of Common Stock in an open-market transaction at a price of $0.2855 per share."
• "Except as set forth above, the Reporting Persons have not effected any other transactions in the Common Stock since September 4, 2026."

Industry Context

StockSavvy.ai notes that Schedule 13D filings are common for institutional investors and significant shareholders who acquire more than 5% of a company's stock. Amendments typically reflect changes in ownership, investment strategy, or the acquisition/disposition of securities. The context here is an active investment management firm adjusting its position in a publicly traded company.

Stakeholder Impact

• Shareholders: The minor sale of shares by Lagoda Investment Management may have a negligible impact on share price, but the continued 5.9% ownership signals ongoing institutional interest.
• Creditors: No direct impact is indicated.
• Employees: No direct impact is indicated.
• Suppliers: No direct impact is indicated.
• Customers: No direct impact is indicated.

Next Steps

• The reporting persons will continue to monitor the issuer's business, securities, and other relevant matters.
• Future transactions in VolitionRx Limited's common stock will be subject to ongoing review and may result in further filings.
• The reporting persons may engage in discussions with management or other shareholders regarding the issuer's business.

Key Dates

Keywords

VolitionRx Limited, Lagoda Investment Management, Schedule 13D, Beneficial Ownership, Common Stock, Warrants, Investment Management